Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Of Related Party Transactions For The Period October 1, 2022 To March 31, 2023.
Disclosure of Related Party Transactions For The Period October 1, 2022 to March 31, 2023.27-05-2023
27-05-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement Under Regulation 30 (LODR)-Appointment Of Secretarial Auditor And Internal Auditor
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 27, 2023 has approved the appointment of M/s. Nilesh A. Pradhan & Co. LLP, Practicing Company Secretary as a Secretarial Auditor and M/s. Vishal Bhanushali & Associates, Chartered Accountant as an Internal Auditor of the Company. The Information required to be submitted pursuant to Regulation 30 of the Listing Regulations is marked and attached as ''Annexure-A & B''.27-05-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Financial Result For The Period Ended 31St March, 2023
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. May 27, 2023 has inter-alia considered and approved the Audited Financial Results for the year ended on March 31, 2023. Please find attached: Audited Financial Results for the year ended on March 31, 2023 along with statement of Assets & Liabilities and Cash Flow Statement, Auditors'''' Report, and Declaration about unmodified opinion in audit report.27-05-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, 27 May, 2023
Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 27th May, 2023 which was commenced at 03:30 P.M. and concluded at 05:20 PM. Attached Agenda items were approved in the meeting.27-05-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Audited Financial Results For The Period Ended On March 31, 2023
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2023 ,inter alia, to consider and approve Audited Financial Results for the quarter and financial year ended on March 31, 2023. This is to further inform that pursuant to the Company''''s Code of Conduct for Prohibition of Insider Trading, framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015; the trading window for all the Directors, Key Managerial Personnel, Designated persons and their immediate relatives shall remain closed and will re-open after 48 hours of the declaration of the financial results of the Company for the quarter and year ended 31st March, 2023.20-05-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Non Applicability Of Statement Of Deviation(S) Or Variation(S) Under Regulation 32 Of SEBI (LODR) Regulations, 2015
Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/162/2019 dated December 24, 2019 and with reference to email received from BSE dated 19.04.2023 with respect to Non-submission of Statement of Deviation(s) or Variation (s) for the quarter ended December 31, 2022 the Company hereby confirms, that there has been no deviation(s) or variation(s) in the use of the Proceeds raised through the Preferential Issues. Hence, the Statement of Deviation(s) or Variation(s) is not applicable to the Company.26-04-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Aspira Pathlab & Diagnostics Ltd 2 CIN NO. L85100MH1973PLC289209 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-2023, 2023-2024 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-2022,2022-2023 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Priya PandeyDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Balkrishna Talawadekar Designation : -Chief Financial Officer Date: 22/04/202322-04-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Certification Under Regulation 40(9) Read With Regulation 40(10) Of The SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2023
Certification under Regulation 40(9) read with Regulation 40(10) of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 202314-04-2023
Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAspira Pathlab & Diagnostics Ltd 2CIN NO.L85100MH1973PLC289209 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Priya Pandey Designation: Company Secretary and Compliance Officer EmailId: priya.pandey@aspiradiagnostics.com Name of the Chief Financial Officer: Balkrishan Talawadekar Designation: Chief Financial Officer EmailId: balkrishna.talawadekar@aspiradiagnostics.com Date: 11/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.11-04-2023